Search clinical trials for: budesonide/formoterol (Symbicort)

Total 814 results

AstraZeneca

Completed

Efficacy of Symbicort pMDI Administered Once Daily in Children and Adolescents During 12 Weeks - SPROUT

Asthma
AstraZeneca

Completed

Long-Term Safety of Symbicort in Asthmatic Children - SAPLING

Asthma
Istituto per la Ricerca e l'Innovazione Biomedica

Completed

The Use of an Innovative Device for Therapeutic Adherence in Pediatric Asthma

Asthma

Italy
AstraZeneca

Completed

Study to Investigate Real Life Effectiveness of Symbicort Maintenance and Reliever Therapy in Asthma Patients Across Asia (SMARTASIA)

Asthma

China, Taiwan, Thailand, India, Indonesia
AstraZeneca
Parexel

Completed

A Study to Assess How Much Drug Reaches the Blood When Given From Symbicort pMDI With Spacer Compared to That of Symbicort pMDI Without Spacer in Healthy Volunteers

Study is Being Conducted in Healthy Volunteers

United Kingdom
AstraZeneca

Completed

Titratable Dosing in Moderate to Severe Asthmatics

Asthma
Orion Corporation, Orion Pharma

Completed

Pharmacokinetic Study to Compare Absorption of Budesonide/Formoterol Easyhaler and Symbicort Turbuhaler

Asthma

Finland
Orion Corporation, Orion Pharma

Completed

To Confirm Equivalent Bronchodilator Efficacy of the Test Product Compared to the Reference Product (BUFODIL)

Asthma

Bulgaria
AstraZeneca

Completed

Non-interventional Surveillance of Effectiveness of Symbicort® Maintenance And Reliever Therapy (Symbicort® SMART) in the Treatment of Moderate and Severe Asthma

Asthma

Croatia
Actavis Inc.
Teva Pharmaceuticals USA

Completed

Randomized, Placebo-Controlled, Multidose, Study Comparing Generic Budesonide/Formoterol Fumarate Dihydrate to Symbicort® in Asthmatic Participants

Asthma

United States
Western Sky Medical Research
AstraZeneca

Completed

Comparing Bronchodilation of Symbicort With and Without Valved Holding Chamber (Aerochamber Plus) (WSMR2)

Asthma

United States
AstraZeneca

Completed

Phase4/Symbicort® Versus Pulmicort Flexhaler® in African Americans (Titan)

Asthma

United States
AstraZeneca

Completed

Gemini Symbicort pMDI

Mild or Moderate Asthma
AO GENERIUM

Completed

An Efficacy and Safety Study of Genolar® and Xolar® in the Persistent Atopic Bronchial Asthma (NAP)

Bronchial Asthma

Russian Federation
AstraZeneca

Completed

Efficacy and Safety Study of Symbicort® Turbuhaler® Versus Oxis® Turbuhaler® in Chronic Obstructive Pulmonary Disease (COPD) Patients (SUMIRE)

Chronic Obstructive Pulmonary Disease

Korea, Republic of, Poland, Russian Federation, Vietnam, Philippines, Ukraine, Japan, Taiwan, India
AstraZeneca

Completed

Physician and Patient Perception of Adjustable Maintenance Dosing of Symbicort Turbuhaler (REALITY)

Perception of Physicians & Patients of AMD
Orion Corporation, Orion Pharma

Completed

Pharmacokinetic Study Comparing Budesonide/Formoterol Easyhaler and Symbicort Turbuhaler Forte (ADECO)

Asthma

Germany
AstraZeneca

Completed

Symbicort Maintenance and Reliever Therapy - Experience in Real Life Setting in Malaysia (SMARTER)

Asthma

Malaysia
AstraZeneca

Completed

An Exploratory Study to Characterise Changes in Airway Inflammation, Symptoms, Lung Function and Reliever Use in Adult Asthma Patients

Asthma | Airway Inflammation

United Kingdom
AstraZeneca

Completed

Study Comparing Dual Combination of Product (Budesonide and Formoterol) Given Via Two Different Inhalers. To See Which One Results in the Best Effect on Breathing.

Chronic Obstructive Pulmonary Disease (COPD)

Germany
Mundipharma Research Limited

Completed

Assessment of the Efficacy and Safety of FlutiForm® pMDI 125/5 µg (2 Puffs Bid) Versus Symbicort® Turbohaler® 200/6 µg (2 Puffs Bid) in Adolescent and Adult Subjects With Moderate to Severe Persistent, Reversible Asthma

Asthma

Poland, Bulgaria, Romania, India, Hungary
Research in Real-Life Ltd
Teva Branded Pharmaceutical Products R&D, Inc.; University of Sydney; The University... and other collaborators

Completed

Comparing Maintenance of Device Mastery With Turbohaler© vs. Spiromax© in Healthcare Professionals naïve to Both Devices (HCP-ELIOT)

Asthma
Pearl Therapeutics, Inc.

Completed

Pharmacokinetics and Safety Study of PT010 in Healthy Subjects

COPD

United States
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Study to Evaluate the Mastery of Inhaler Technique for Budesonide Formoterol (BF) SPIROMAX® as Compared to SYMBICORT® TURBOHALER® as Treatment for Adult Participants With Asthma (ELIOT)

Asthma

United Kingdom
Orion Corporation, Orion Pharma

Completed

Pharmacokinetic Pilot Study on Budesonide/Formoterol Device-metered Dry Powder Inhaler

Healthy

Finland
AstraZeneca

Completed

A Comparison of SYMBICORT® pMDI With Formoterol Turbuhaler® in Subjects With COPD

Chronic Obstructive Pulmonary Disease

United States, Peru, South Africa, Argentina, Mexico, Brazil, Chile, Colombia, Venezuela
AstraZeneca

Completed

An Efficacy Study Comparing SYMBICORT® Pressurised Metered Dose Inhaler (pMDI) With Budesonide Hydrofluoroalkanes (HFA) pMDI, in Hispanic Subjects With ICS Dependent Asthma

Asthma

United States, Puerto Rico
University Hospital, Antwerp
AstraZeneca

Completed

Assess Particle Deposition and Acute Effects of Symbicort® Forte Turbohaler®) in COPD Patients.

Chronic Obstructive Pulmonary Disease

Belgium
AstraZeneca

Completed

A Safety and Efficacy Study of Symbicort Turbuhaler Compared With Standard Chronic Obstructive Pulmonary Disease (COPD) Treatment in Japan

Chronic Obstructive Pulmonary Disease

Japan
Orion Corporation, Orion Pharma

Completed

Comparison of Absorption of Budesonide and Formoterol From Budesonide/Formoterol Easyhaler and Symbicort Turbuhaler

Asthma

Finland
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Efficacy and Safety Evaluation of Budesonide/Formoterol SPIROMAX® Inhalation Powder Versus SYMBICORT® TURBOHALER®

Asthma

Austria, Belgium, Czechia, Denmark, Finland, France, Germany, Hungary, Israel, Italy, Netherlands, Poland, Russian Federation, Spain, Sweden, United Kingdom
AstraZeneca

Completed

Symbicort Rapihaler Therapeutic Equivalence Study (ESTHER)

Bronchial Asthma

Bulgaria, Czech Republic, Poland, Hungary
AstraZeneca

Completed

Efficacy of Symbicort Versus Its Monocomponents - SPRUCE 80/4.5

Asthma
AstraZeneca

Completed

Efficacy of Symbicort Versus Its Monocomponents - SPRUCE 160/4.5

Asthma
Zambon SpA

Completed

A Clinical Study to Evaluate Z7200 (Budesonide/Formoterol) Pharmacokinetics Profile in Healthy Volunteers

Asthma

United Kingdom
Kindeva Drug Delivery

Completed

Randomized, Placebo-controlled, Multi-dose, Study Comparing Budesonide/Formoterol to Symbicort® in Asthmatic Patients

Asthma

United States
Assistance Publique - Hôpitaux de Paris

Terminated

Protective Role of Inhaled Steroids for Covid-19 Infection (INHASCO)

Covid-19 Infection | Hospitalization in Respiratory Disease Department

France
AstraZeneca

Completed

Efficacy and Safety Study of Symbicort Turbuhaler in Chinese Patients With COPD

Chronic Obstructive Pulmonary Disease

China
AstraZeneca

Completed

Symbicort in Asthmatic Children - SEEDLING

Asthma
AstraZeneca

Terminated

Symbicort Single Inhaler Therapy vs Conventional Best Practice for the Treatment of Persistent Asthma in Adults

Asthma, Bronchial

Spain
AstraZeneca

Completed

A Comparison of SYMBICORT® pMDI With Budesonide HFA pMDI in African American Subjects With Asthma.

Asthma

United States
Zambon SpA

Completed

Clinical Study to Evaluate Z7200 Pharmacokinetics Profile

Asthma

United Kingdom
AstraZeneca

Completed

A 6 Month Safety Study Comparing Symbicort With Inhaled Corticosteroid Only in Asthmatic Adults and Adolescents

Asthma

United States, Brazil, Bulgaria, Czech Republic, Italy, Korea, Republic of, Mexico, Peru, Poland, Russian Federation, South Africa, United Kingdom, Vietnam, Germany, Philippines, Romania, Ukraine, Argentina, Chile, Puerto Rico, ... and more
AstraZeneca

Completed

Comparing the Efficacy of Symbicort® pMDI and Formoterol Turbuhaler in Reducing Exacerbations in Patients With Cronic Obstructive Pulmonary Disease (RISE)

COPD Patients

United States, Spain, Bulgaria, Mexico, Poland, South Africa, Germany, Argentina, Chile, Czechia, Puerto Rico
Medical University of Warsaw

Completed

Optimal Type of Inhaler in Cough Variant- or Cough Predominant Asthma

Asthma | Cough Variant Asthma

Poland
Pearl Therapeutics, Inc.

Completed

Study to Assess the Safety and Efficacy of PT010, PT003, and PT009 in Japanese Subjects With COPD Compared With Symbicort® Turbohaler®

COPD

Japan
Zambon SpA
FLUIDDA nv

Completed

Study to Compare the Effects of Z7200 And Symbicort® Turbohaler on Respiratory Imaging Parameters in Asthmatic Patients

Asthma | Asthma Chronic | Asthmatic | Asthma Bronchial

Belgium
Pearl Therapeutics, Inc.

Completed

Phase I Study Evaluating the Safety and Pharmacokinetics of Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol (BGF MDI) in Healthy Volunteers

Healthy Volunteers

United States
AstraZeneca

Completed

Efficacy of Symbicort pMDI Administered Once Daily in Adolescents and Adults During 12 Weeks - STEM

Asthma
Pearl Therapeutics, Inc.

Completed

Study to Assess Efficacy and Safety of PT009 Compared to PT005, PT008, and Symbicort® Turbuhaler® on Lung Function Over 24-Weeks in Subjects With Moderate to Very Severe COPD (telos)

Chronic Obstructive Pulmonary Disorder

United States, Canada, Germany, Hungary, Korea, Republic of, Poland, Russian Federation, Czechia

3

Subscribe